Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Clinical trial NCT03579966 · TERMINATED
Trial details
- NCT number
- NCT03579966
- Sponsor
- Catalyst Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-11
- Primary completion
- 2022-08-05
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.